Novartis Hid Bogus Data, May Face Penalties, FDA Says
A Novartis-owned gene therapy company covered up data manipulation when seeking approval for a muscle disease medication and could face criminal sanctions, the U.S. Food and Drug Administration said Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article